Honeywell International Inc vs Organon & Co. Common Stock — how do they compare? Honeywell International Inc trades at $208.11 (market cap $65.70B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Honeywell International Inc is far larger — about 18.1× Organon & Co. Common Stock's market cap, and Honeywell International Inc pays the higher dividend (1.35%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Organon & Co. Common Stock for 0 Days on average.
| HON | OGN | |
|---|---|---|
Market Cap | $65.70B | $3.62B |
Volume | 1,861,268 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $248.79 | $13.81 |
52-Week Low | $188.14 | $5.70 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $90.49B | $11.04B |
Dividend Yield | 1.35% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.61, down 0.97% on the day, as technical indicators show bearish momentum despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.95 exceeding expectations of $1.83. Recent news highlights Honeywell's $300 million contract win for the Dangote refinery project and the company's strategic focus on automation following its corporate restructuring into three separate entities.
Honeywell presents a compelling value opportunity with attractive valuation multiples (P/E of 7.97, EV/EBITDA of 6.74) and strong profitability metrics (ROE 47.43%, net margin 21.58%). However, investors face risks from increasing debt levels and the execution challenges of the corporate spin-off strategy. Analyst consensus remains bullish with a $259.25 price target representing 25% upside potential from current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →